CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

• ClinicalTrials.gov Identifier: NCT01848990
• Recruitment Status: Completed
• First Posted: May 8, 2013
• Results First Posted: October 29, 2014
• Last Update Posted: November 7, 2018
• Sponsor: Halozyme Therapeutics
• Information provided by (Responsible Party): Halozyme Therapeutics

Study Description

Brief Summary:

The primary objectives of this study are to compare the difference in glycosylated hemoglobin (HbA1c) from baseline to Month 6 using Hylenex recombinant preadministration in continuous subcutaneous insulin infusion (CSII) versus standard CSII and to evaluate the safety of Hylenex recombinant preadministration, including local tolerability, adverse events, and hypo- and hyperglycemia rates.

Condition or disease	Intervention/treatment	Phase
Type 1 Diabetes Mellitus	Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Precommercial Hylenex recombinant (hyaluronidase human injection); Drug: Insulin lispro; Drug: Insulin aspart; Drug: Insulin glulisine	Phase 4

Detailed Description:

This Phase 4 study is designed to demonstrate noninferiority of pretreatment with Hylenex recombinant in the CSII setting to rapid-acting analog insulin alone with respect to glycemic control as assessed by changes in HbA1c in participants with Type 1 diabetes mellitus.

Total duration of study treatment is 24 months. However, according to the study design, the primary outcome measure is to be assessed at 6 months and an interim analysis is to be completed at 6 months for the secondary outcome measures and adverse events. Therefore, data reported in this clinical trials record is for the 6-month interim analysis.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 456 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII)
• Study Start Date: March 2013
• Actual Primary Completion Date: February 2014
• Actual Study Completion Date: September 2014

Arms and Interventions

Arm	Intervention/treatment
Experimental: Commercial Hylenex Recombinant (Formulation 1); Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).	Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Other Names: Formulation 1; Hylenex; Recombinant human hyaluronidase (rHuPH20); Drug: Insulin lispro; Other Names: Humalog; Lispro; Drug: Insulin aspart; Other Names: Novolog; Aspart; Drug: Insulin glulisine; Other Names: Apidra; Glulisine
Experimental: Precommercial Hylenex Recombinant (Formulation 2); Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).	Drug: Precommercial Hylenex recombinant (hyaluronidase human injection); Other Names: Formulation 2; Hylenex; rHuPH20; Drug: Insulin lispro; Other Names: Humalog; Lispro; Drug: Insulin aspart; Other Names: Novolog; Aspart; Drug: Insulin glulisine; Other Names: Apidra; Glulisine
Active Comparator: Standard Rapid-Acting Insulin CSII; Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.	Drug: Insulin lispro; Other Names: Humalog; Lispro; Drug: Insulin aspart; Other Names: Novolog; Aspart; Drug: Insulin glulisine; Other Names: Apidra; Glulisine

Outcome Measures

Primary Outcome Measures :

1. Change From Baseline to 6 Months in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline; 6 Months ]
   Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
2. Change From Baseline to 12 Months in HbA1c [ Time Frame: Baseline; 12 Months ]
   Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Secondary Outcome Measures :

1. Rates of Hypoglycemia Events (HE) to Month 6 [ Time Frame: After Month 1 up to Month 6 ]
   Overall rates of hypoglycemia (defined as blood glucose ≤70 milligrams per deciliter [mg/dL] and <56 mg/dL) were based on measurements after 1 month up to 6 months. A severe HE was classified as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. A nocturnal HE was classified as an event with a blood glucose of ≤70 mg/dL with start time between 2300 and 0600, inclusive. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.
2. Rates of HEs to Month 12 [ Time Frame: After Month 1 up to Month 12 ]
   Overall rates of hypoglycemia (defined as blood glucose ≤70 milligrams per deciliter [mg/dL] and <56 mg/dL) were based on measurements after 1 month up to 12 months. A severe HE was classified as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. A nocturnal HE was classified as an event with a blood glucose of ≤70 mg/dL with start time between 2300 and 0600, inclusive. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.
3. Rates of Hyperglycemia Events to Month 6 [ Time Frame: After Month 1 up to Month 6 ]
   Overall rates of hyperglycemia (defined as blood glucose >240 mg/dL and >300 mg/dL) were based on measurements after 1 month up to 6 months. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.
4. Rates of Hyperglycemia Events to Month 12 [ Time Frame: After Month 1 up to Month 12 ]
   Overall rates of hyperglycemia (defined as blood glucose >240 mg/dL and >300 mg/dL) were based on measurements after 1 month up to 12 months. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.
5. Mean Glucose Excursions at 6 Months [ Time Frame: After Month 1 up to Month 6 ]
   A 4-hour postprandial glucose excursion was measured for 3 meals after 1 month up to 6 months. For each of the 3 meals, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal (for measurements taken within 15 minutes before a meal). The average of all excursions is presented. Least Squares (LS) means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.
6. Mean Glucose Excursions at 12 Months [ Time Frame: After Month 1 up to Month 12 ]
   A 4-hour postprandial glucose excursion was measured for 3 meals after 1 month up to 12 months. For each of the 3 meals, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal (for measurements taken within 15 minutes before a meal). The average of all excursions is presented. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.
7. Standard Deviation of Self-Monitoring Blood Glucose Values at 6 Months [ Time Frame: After Month 1 up to Month 6 ]
   Standard deviation of self-monitoring blood glucose values was calculated based on measurements taken within 15 minutes before a meal, 1 month and up to 6 months after study drug administration. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.
8. Standard Deviation of Self-Monitoring Blood Glucose Values at 12 Months [ Time Frame: After Month 1 up to Month 12 ]
   Standard deviation of self-monitoring blood glucose values was calculated based on measurements taken within 15 minutes before a meal, 1 month and up to 12 months after study drug administration. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.
9. Number of Participants Achieving HbA1c <7.0% and HbA1c ≤6.5% at Month 12 [ Time Frame: Month 12 ]
   The number of participants achieving HbA1c goals of <7% and ≤6.5% was calculated.
10. Change From Baseline in Body Weight to Month 12 [ Time Frame: Baseline; Week 2; Months 1, 2, 3, 4, 6, 9, and 12 ]
    Baseline is defined as the last measurement prior to randomization.
11. Average of Daily Insulin Doses (Bolus, Basal, and Total) [ Time Frame: from Randomization up to Month 12 ]
    The daily bolus insulin dose is calculated as the daily prandial (occurring before a meal) insulin dose plus the daily corrective insulin dose. Cumulative basal dosage is to generally be within 40% to 60% of the total daily dose.
12. Average Carbohydrate Factor (CarbF) Values [ Time Frame: Month 1 to Month 12 ]
    CarbF is calculated as 2.6 * weight (pounds) / total daily dose of insulin (grams per unit).
13. Average Correction Factor (CorrF) Values [ Time Frame: Month 1 to Month 12 ]
    CorrF is calculated as 1960 / total daily dose of insulin (milligrams/[deciliter*unit]).
14. Average of Bolus Times Relative to Meal Times [ Time Frame: Month 1 to Month 12 ]
    The average meal bolus timing relative to meal time is defined as the minutes between the start time of a meal bolus and the start time of a meal.
15. Average Glucose, Median Glucose, and Average Daily Standard Deviation [ Time Frame: Randomization to Month 12 ]
    For each participant, the following continuous glucose monitoring (CGM) parameters were calculated using CGM values recorded after Randomization up to Month 12: average glucose, median glucose, and average daily standard deviation.
16. Time Per Day <56 Milligrams Per Deciliter (mg/dL), ≤70 mg/dL, >70 mg/dL, <140 mg/dL, ≥140 mg/dL, Outside of 71 to 180 mg/dL, and Outside of 71 to 139 mg/dL [ Time Frame: Randomization to Month 12 ]
    For each participant, the following CGM parameters were calculated using CGM values recorded after Randomization up to Month 12: time per day spent in the pre-defined glucose classes.
17. Area Per Day <56 mg/dL, ≤70 mg/dL, ≥140 mg/dL, Outside of 71 to 180 mg/dL, and Outside of 71 to 139 mg/dL [ Time Frame: Randomization to Month 12 ]
    For each participant, the following continuous glucose monitoring (CGM) parameters were calculated using CGM values recorded after Randomization up to Month 12: area per day spent in the pre-defined glucose classes. The area per day for a specific glucose concentration range (e.g., <56 mg/dL) is the sum of the area under the curve with glucose concentration falling in the specific glucose concentration range (e.g., <56 mg/dL). For example, if the glucose stays constant at 50 mg/dL for the whole day (1,440 minutes), the area per day for glucose < 56 mg/dL equals: 50*1440 = 72,000 mg*minutes/dL.
18. Change From Baseline in Weighted Impact ADDQoL Values at Month 12 [ Time Frame: Baseline; Month 12 ]
    The Audit of Diabetes Dependent Quality of Life (ADDQoL) is a validated, diabetes-specific questionnaire to evaluate the participant's assessment of quality of life (QoL). Participants rated the impact of diabetes on 19 applicable domains on a scale from -3 (maximum negative impact) to +3 (maximum positive impact) and then rated the importance of those domains for their QoL on a scale from 3 (very important) to 0 (not at all important). Impact ratings were multiplied by the corresponding importance ratings to provide a weighted-impact score for each domain from -9 (maximum negative impact) to +9 (maximum positive impact).
19. Change From Baseline in Average Weighted Impact ADDQoL Values at Month 12 [ Time Frame: Baseline; Month 12 ]
    The ADDQoL is a validated, diabetes-specific questionnaire to evaluate the participant's assessment of QoL. Participants rated the impact of diabetes on 19 applicable domains on a scale from -3 (maximum negative impact) to +3 (maximum positive impact) and then rated the importance of those domains for their QoL on a scale from 3 (very important) to 0 (not at all important). Impact ratings were multiplied by the corresponding importance ratings to provide a weighted-impact score for each domain from -9 (maximum negative impact) to +9 (maximum positive impact). Weighted impact scores were summed and divided by the number of applicable domains to give an overall Average Weighted Impact (AWI) score (higher values represent more positive impact). If there were less than 13 non-missing weighted-impact values, AWI was not to be calculated. Baseline is defined as the last measurement prior to randomization.
20. Change From Baseline in DTSQs and DTSQc at Month 12 [ Time Frame: Baseline; Month 12 ]
    The Diabetes Treatment Satisfaction Questionnaire-status version (DTSQs) and DTSQ-change version (DTSQc) are validated tools to assess treatment satisfaction and change in treatment satisfaction after therapy changes have occurred. The scale total was computed by adding the 6 items (1, 4, 5, 6, 7, and 8) to produce the Treatment Satisfaction scale total, which has a minimum of 0 and a maximum of 36 on the DTSQs and a minimum of -18 and a maximum of 18 on the DTSQc. Higher scores represent greater satisfaction. If any of the 6 item scores were missing and the numbers of missing scores were less than the number of non-missing scores, the Treatment Satisfaction scale score was to be computed by taking the average of the existing scores and multiplying the average by 6. If there were less than 4 non-missing item scores, the Treatment Satisfaction scale score was not to be calculated. Baseline is defined as the last measurement prior to randomization.
21. Mean Time to Change Infusion Site [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program.
22. Mean Additional Time for Hylenex Pre-administration [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program.
23. Number of Participants With the Indicated Responses to the Question Regarding the Difficulty of Infusion Site Change [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program.
24. Number of Participants With the Indicated Responses to the Device Handling Questions [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program. Question 1: Achieve excellent post meal glucose control; Question 2: Insulin responds quickly when basal rate is changed; Question 3: Insulin responds quickly when correction bolus is given.
25. Mean Times Per Week Participants Said They Were Eating to Avoid Going Low Due to Late Insulin Action [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female of age 18 years or older with a history of T1DM for at least 12 months
2. Glycosylated hemoglobin (HbA1c) 6.5% to 9.5% (inclusive) based on central laboratory results
3. Fasting C-peptide <0.6 nanograms per milliliter (ng/mL)
4. Current use of an insulin pump compatible with available tubing for Hylenex recombinant infusion and use of an infusion set compatible with the tubing available or willingness to switch to an infusion set compatible with tubing available for infusion of Hylenex recombinant
5. Current treatment at the time of screening with insulin <300 units per day (U/day)
6. Participants who routinely use continuous glucose monitoring (CGM) (defined as average CGM use 5 or more days per week over the preceding 3 months) and those who do not routinely used CGM are both eligible for inclusion in the study. Intermittent use of CGM is also acceptable but will not be a criterion use for stratified randomization.
7. Participants should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug infusions and assessments required in this protocol.

Exclusion Criteria:

1. Type 2 diabetes
2. Known or suspected allergy to any component of any of the study drugs in this study
3. Severe proliferative retinopathy or maculopathy, and/or gastroparesis, and/or severe neuropathy, in particular autonomic neuropathy, of such severity as to impede the participant's ability to comply with protocol procedures, as judged by the Investigator
4. History of transmural myocardial infarction, congestive heart failure and uncontrolled hypertension (diastolic blood pressure [BP] consistently >100 millimeters of mercury [mmHg]) are exclusionary
5. As judged by the Investigator, clinically significant active disease of the gastrointestinal, cardiovascular (including history of stroke, history of arrhythmia, or conduction delays on electrocardiogram [ECG]), hepatic, neurological, renal, genitourinary, pulmonary, or hematological systems of such severity as to impede the participant's ability to comply with protocol procedures
6. History of any illness or disease that in the opinion of the Investigator might confound the results of the study or pose additional risk in administering the study drugs to the participant
7. As judged by the Investigator, clinically significant findings in routine laboratory data at screening
8. Use of drugs that may interfere with the interpretation of study results or are known to cause clinically relevant interference with hyaluronidase action, insulin action, glucose utilization, or recovery from hypoglycemia (including systemic pharmacologic corticosteroid). Use of pramlintide or a glucagon-like peptide [GLP]-1 receptor agonist is not exclusionary but participants using these agents will be subjected to stratified randomization. Use of aspirin (acetylsalicylic acid [ASA]) up to 325 milligrams (mg)/day is not exclusionary but should be noted for analysis.
9. Hypoglycemic unawareness of such severity as to impede the participant's ability to comply with protocol procedures, as judged by the Investigator.
10. Current addiction to alcohol or substance abuse as determined by the Investigator.
11. Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate contraceptive measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives, and/or barrier methods). Abstinence alone is not considered an adequate contraceptive measure for the purposes of this study.
12. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation in this study

Contacts and Locations

Locations

United States, California

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Concord, California, United States, 94520

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Encino, California, United States, 91436

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Escondido, California, United States, 92026

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Greenbrae, California, United States, 94904

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

La Jolla, California, United States, 92037

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

San Mateo, California, United States, 94401

United States, Colorado

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Aurora, Colorado, United States, 80045

United States, Florida

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Hollywood, Florida, United States, 33021

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Miami, Florida, United States, 33136

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Miami, Florida, United States, 33156

United States, Georgia

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Atlanta, Georgia, United States, 30318

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Roswell, Georgia, United States, 30076

United States, Idaho

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Idaho Falls, Idaho, United States, 83404

United States, Iowa

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Des Moines, Iowa, United States, 50314

United States, Kansas

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Wichita, Kansas, United States, 67226

United States, Kentucky

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Lexington, Kentucky, United States, 40503

United States, Maryland

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Hyattsville, Maryland, United States, 20782

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Rockville, Maryland, United States, 20852

United States, Michigan

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Detroit, Michigan, United States, 48202

United States, Minnesota

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Minneapolis, Minnesota, United States, 55416

United States, Montana

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Butte, Montana, United States, 59701

United States, Nevada

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Henderson, Nevada, United States, 89052

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Las Vegas, Nevada, United States, 89148

United States, New York

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

New Hyde Park, New York, United States, 11042

United States, North Carolina

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Asheville, North Carolina, United States, 28803

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Durham, North Carolina, United States, 27713

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Morehead City, North Carolina, United States, 28557

United States, Ohio

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Cincinnati, Ohio, United States, 45219

United States, Oregon

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Portland, Oregon, United States, 97210

United States, Tennessee

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Bartlett, Tennessee, United States, 38133

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Chattanooga, Tennessee, United States, 37411

United States, Texas

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Austin, Texas, United States, 78731

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Dallas, Texas, United States, 75231

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Round Rock, Texas, United States, 78681

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

San Antonio, Texas, United States, 78258

United States, Washington

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Olympia, Washington, United States, 98502

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Renton, Washington, United States, 98057

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Seattle, Washington, United States, 98105

United States, Wisconsin

For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time

Madison, Wisconsin, United States, 53717

Sponsors and Collaborators

Halozyme Therapeutics

Investigators

• Study Director: Douglas Muchmore, MD; Halozyme Therapeutics

More Information

Additional Information:

Related Info 

• Responsible Party: Halozyme Therapeutics
• ClinicalTrials.gov Identifier: NCT01848990
• Other Study ID Numbers: Halo-117-403
• First Posted: May 8, 2013
• Results First Posted: October 29, 2014
• Last Update Posted: November 7, 2018
• Last Verified: October 2018

Keywords provided by Halozyme Therapeutics:

Type 1 Diabetes Mellitus; Sub Cutaneous Insulin Infusion; Rapid Acting Analog Insulin; Hylenex; Halozyme; Phase 4

Additional relevant MeSH terms:

Diabetes Mellitus, Type 1; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Insulin; Insulin, Globin Zinc; Insulin Aspart; Insulin Lispro; Insulin glulisine; Hypoglycemic Agents; Physiological Effects of Drugs